Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) Invested Capital: 2018-2025

Historic Invested Capital for Bicycle Therapeutics (BCYC) over the last 8 years, with Sep 2025 value amounting to $618.5 million.

  • Bicycle Therapeutics' Invested Capital fell 25.58% to $618.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $618.5 million, marking a year-over-year decrease of 25.58%. This contributed to the annual value of $793.1 million for FY2024, which is 113.80% up from last year.
  • As of Q3 2025, Bicycle Therapeutics' Invested Capital stood at $618.5 million, which was down 7.54% from $668.9 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Invested Capital ranged from a high of $896.2 million in Q2 2024 and a low of $142.1 million during Q2 2021.
  • Moreover, its 3-year median value for Invested Capital was $618.5 million (2025), whereas its average is $559.5 million.
  • In the last 5 years, Bicycle Therapeutics' Invested Capital dropped by 29.32% in 2023 and then skyrocketed by 307.19% in 2024.
  • Bicycle Therapeutics' Invested Capital (Quarterly) stood at $346.3 million in 2021, then declined by 21.80% to $270.8 million in 2022, then soared by 36.98% to $370.9 million in 2023, then skyrocketed by 113.80% to $793.1 million in 2024, then dropped by 25.58% to $618.5 million in 2025.
  • Its last three reported values are $618.5 million in Q3 2025, $668.9 million for Q2 2025, and $740.3 million during Q1 2025.